Smuggler,
Using your backward-looking (no pun intended) approach, here are my simple breakeven calculations based exclusively on the following numbers extracted from the 2007 results:
($'000)
Sales $11,060
GP $9,868
GP Margin 89.2%
Cash Expenses $14,974 comprising…
- Employee costs $9,709
- Underlying (cash) overheads $3,265
- R&D Costs $2,000 (recurring as stated in the report)
The implied cash shortfall is:
GP$ less Cash Expenses ($9,868 - $14,974) = $5,106.
The breakeven sales/revenues position based on the contribution margin of 89.2% is:
Cash Expenses / GP Margin ($14,974/89.2%) = $16,787
Given that Sales in 2007 were $11,060, the implied Sales/Revenue gap is therefore $5,727.
Now, if you also wish to cover what the company called its (cash) “one-off costs” in 2007 being:
- M&A $500
- Technology compliance $400
then sales will have to increase by an additional $1,009 ($900/89.2%).
The above calculations to not consider working capital adjustments, investing activities, disposal or acquisition activities etc.
Please DYOR.
- Forums
- ASX - By Stock
- full year report analysis
Smuggler,Using your backward-looking (no pun intended) approach,...
-
- There are more pages in this discussion • 9 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add SEN (ASX) to my watchlist
|
|||||
Last
1.4¢ |
Change
0.000(0.00%) |
Mkt cap ! $21.99M |
Open | High | Low | Value | Volume |
0.0¢ | 0.0¢ | 0.0¢ | $0 | 0 |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
8 | 1570571 | 1.3¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
1.4¢ | 307452 | 5 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
8 | 1570571 | 0.013 |
8 | 1836664 | 0.012 |
2 | 137272 | 0.011 |
2 | 150000 | 0.010 |
2 | 495000 | 0.008 |
Price($) | Vol. | No. |
---|---|---|
0.014 | 307452 | 5 |
0.015 | 10283333 | 3 |
0.016 | 352000 | 3 |
0.019 | 4500 | 1 |
0.020 | 35358 | 1 |
Last trade - 11.21am 03/07/2024 (20 minute delay) ? |
Featured News
SEN (ASX) Chart |
Day chart unavailable
The Watchlist
RCE
RECCE PHARMACEUTICALS LTD
James Graham, CEO
James Graham
CEO
Previous Video
Next Video
SPONSORED BY The Market Online